depression

News

J&J's Spravato gets another lift with new FDA approval

Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.

News

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

News

Neumora laid low by depression trial failure

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.

News

Drug-digital dual therapy for depression starts phase 2

Gate Neurosciences' antidepressant apimostinel has started a proof-of-concept study to see if its efficacy can be boosted by a digital training tool.

News

Orexo exits depression DTx alliance with GAIA

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

News

Compass Pathways' chief executive Kabir Nath

Compass points to job cuts as it defers trial readouts

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre

J&J's Spravato gets another lift with new FDA approval

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Neumora laid low by depression trial failure

Drug-digital dual therapy for depression starts phase 2

Orexo exits depression DTx alliance with GAIA

Compass points to job cuts as it defers trial readouts

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

depression

Editor's Picks